The prognostic role of metabolic tumor burden in 18F-FDG PET/CT in the primary staging of rectal cancers

IF 2.3 4区医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING Clinical and Translational Imaging Pub Date : 2024-03-04 DOI:10.1007/s40336-024-00621-8

{"title":"The prognostic role of metabolic tumor burden in 18F-FDG PET/CT in the primary staging of rectal cancers","authors":"","doi":"10.1007/s40336-024-00621-8","DOIUrl":null,"url":null,"abstract":"<h3>Abstract</h3> <span> <h3>Introduction</h3> <p>The prognostic value of FDG PET/CT metabolic tumor burden has been established in various solid tumors, but its significance in the staging of rectal cancer remains underexplored. This study aimed to investigate the prognostic role of FDG PET/CT metabolic tumor burden in the primary staging of rectal cancer.</p> </span> <span> <h3>Methods</h3> <p>A retrospective analysis was conducted on 82 consecutive histology-proven rectal cancer patients, including 30 females (37%), with a mean age of 60.8 years. These patients underwent staging FDG PET/CT, and various metabolic tumor burden parameters (tuSUVmax, tuMTV, wbMTV, tuTLG, wbTLG) were calculated. The study assessed the correlation between metabolic tumor burden parameters and overall survival (OS), progression-free survival (PFS), as well as histopathology, clinical staging, performance status, bone-mineral indexes, hematology, and therapy management strategies.</p> </span> <span> <h3>Results</h3> <p>The study revealed that metabolic tumor burden, along with the presence of sarcopenia and absence of surgery, were significantly and independently associated with overall survival. Notably, a wbTLG cutoff value of 354 effectively discriminated survivors from non-survivors (<em>p</em> = 0.0007) with 83% specificity. Furthermore, higher whole-body tumor burden (wbTLG: <em>p</em> = 0.0090) and low body mass index (<em>p</em> = 0.0231) were significantly linked to an increased risk of disease progression.</p> </span> <span> <h3>Conclusion</h3> <p>This research suggests that whole-body tumor burden assessed through staging FDG PET/CT can serve as an independent imaging biomarker for prognostication in rectal cancer patients.</p> </span>","PeriodicalId":48600,"journal":{"name":"Clinical and Translational Imaging","volume":"68 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Translational Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40336-024-00621-8","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

The prognostic value of FDG PET/CT metabolic tumor burden has been established in various solid tumors, but its significance in the staging of rectal cancer remains underexplored. This study aimed to investigate the prognostic role of FDG PET/CT metabolic tumor burden in the primary staging of rectal cancer.

Methods

A retrospective analysis was conducted on 82 consecutive histology-proven rectal cancer patients, including 30 females (37%), with a mean age of 60.8 years. These patients underwent staging FDG PET/CT, and various metabolic tumor burden parameters (tuSUVmax, tuMTV, wbMTV, tuTLG, wbTLG) were calculated. The study assessed the correlation between metabolic tumor burden parameters and overall survival (OS), progression-free survival (PFS), as well as histopathology, clinical staging, performance status, bone-mineral indexes, hematology, and therapy management strategies.

Results

The study revealed that metabolic tumor burden, along with the presence of sarcopenia and absence of surgery, were significantly and independently associated with overall survival. Notably, a wbTLG cutoff value of 354 effectively discriminated survivors from non-survivors (p = 0.0007) with 83% specificity. Furthermore, higher whole-body tumor burden (wbTLG: p = 0.0090) and low body mass index (p = 0.0231) were significantly linked to an increased risk of disease progression.

Conclusion

This research suggests that whole-body tumor burden assessed through staging FDG PET/CT can serve as an independent imaging biomarker for prognostication in rectal cancer patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

18F-FDG PET/CT 在直肠癌初诊分期中代谢性肿瘤负荷的预后作用

摘要引言 FDG PET/CT 代谢肿瘤负荷在多种实体瘤中的预后价值已被证实，但其在直肠癌分期中的意义仍未得到充分探讨。本研究旨在探讨 FDG PET/CT 代谢肿瘤负荷在直肠癌原发分期中的预后作用。方法对连续 82 例组织学证实的直肠癌患者进行回顾性分析，其中包括 30 名女性（37%），平均年龄为 60.8 岁。这些患者接受了分期 FDG PET/CT 检查，并计算了各种代谢肿瘤负荷参数（tuSUVmax、tuMTV、wbMTV、tuTLG、wbTLG）。研究评估了代谢性肿瘤负荷参数与总生存期（OS）、无进展生存期（PFS）以及组织病理学、临床分期、表现状态、骨矿物质指数、血液学和治疗管理策略之间的相关性。结果研究发现，代谢性肿瘤负荷、肌肉疏松症的存在和未进行手术与总生存期有显著的独立相关性。值得注意的是，354 的 wbTLG 临界值能有效区分存活者和非存活者（p = 0.0007），特异性高达 83%。此外，较高的全身肿瘤负荷（wbTLG：p = 0.0090）和较低的体重指数（p = 0.0231）与疾病进展风险的增加显著相关。结论该研究表明，通过分期 FDG PET/CT 评估的全身肿瘤负荷可作为直肠癌患者预后的独立影像生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Clinical and Translational Imaging Medicine-Radiology, Nuclear Medicine and Imaging

CiteScore

3.60

自引率

4.80%

发文量

期刊介绍： Clinical and Translational Imaging is an international journal that publishes timely, up-to-date summaries on clinical practice and translational research and clinical applications of approved and experimental radiopharmaceuticals for diagnostic and therapeutic purposes. Coverage includes such topics as advanced preclinical evidence in the fields of physics, dosimetry, radiation biology and radiopharmacy with relevance to applications in human subjects. The journal benefits a readership of nuclear medicine practitioners and allied professionals involved in molecular imaging and therapy.